Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
DEN Open|March 31, 2023
Fully covered metallic stents for anastomotic biliary strictures after living donor liver transplantationNaohiro Komatsu, Eisuke Ozawa, Masanori Fukushima, et al.
Anticancer Research|October 3, 2022
Long-term Outcomes and Prognostic Factors of Stereotactic Body Radiotherapy for Hepatocellular CarcinomaKazuyoshi Nagata, Ryu Sasaki, Shinichi Iwatsu, et al.
Crohn'S & Colitis 360|May 19, 2025
Efficacy of Filgotinib in Moderate to Severe Ulcerative Colitis: A Prospective Study Using Partial Mayo Score, Ulcerative Colitis Endoscopic Index of Severity, and Geboes Histopathology ScoreYoshiyuki Shirouzu, Hideki Ishibashi, Masayoshi Kage, et al.
Medicine|May 9, 2020
Study on prevention of hypercapnia by nasal high flow in patients undergoing endoscopic retrograde cholangiopancreatography during intravenous anesthesiaTakao Ayuse, Hironori Sawase, Eisuke Ozawa, et al.
Biomedical Reports|August 20, 2024
Serum immunoglobulin A levels: Diagnostic utility in alcoholic liver disease and association with liver fibrosis in steatotic liver diseaseTatsuki Ichikawa, Mio Yamashima, Shinobu Yamamichi, et al.
Plos One|September 30, 2016
Rapid Increase in Serum Low-Density Lipoprotein Cholesterol Concentration during Hepatitis C Interferon-Free TreatmentSatoru Hashimoto, Hiroshi Yatsuhashi, Seigo Abiru, et al.
Biomedical Reports|January 15, 2024
PIVKA‑II is associated with liver function, bone metabolism, and muscle function in patients with liver diseaseTakuya Honda, Tatsuki Ichikawa, Mio Yamashima, et al.
BMC Anesthesiology|May 9, 2023
Respiratory support with nasal high flow without supplemental oxygen in patients undergoing endoscopic retrograde cholangiopancreatography under moderate sedation: a prospective, randomized, single-center clinical trialHironori Sawase, Eisuke Ozawa, Hiroshi Yano, et al.
Cancers|February 15, 2022
Evaluating the Role of Hepatobiliary Phase of Gadoxetic Acid-Enhanced Magnetic Resonance Imaging in Predicting Treatment Impact of Lenvatinib and Atezolizumab plus Bevacizumab on Unresectable Hepatocellular CarcinomaRyu Sasaki, Kazuyoshi Nagata, Masanori Fukushima, et al.
Pageof 1